You’ve done everything the textbooks say to do. You’ve tried the SSRIs, the SNRIs, maybe a mood stabilizer or two. You’ve sat through months of therapy sessions, adjusted dosages, waited the recommended six weeks for each new medication to take effect—and then waited again when it didn’t. For the estimated one in three people with major depression whose symptoms don’t adequately respond to conventional treatments, the phrase “treatment-resistant depression” isn’t just a clinical label. It’s a lived experience of exhaustion, frustration, and diminishing hope. If this describes your journey, you’re far from alone.
What Makes Depression “Treatment-Resistant”?
Treatment-resistant depression, or TRD, is generally defined as major depressive disorder that hasn’t responded adequately to at least two different antidepressant medications taken at proper doses for sufficient duration. But behind that clinical definition lies a deeply human reality: months or years spent cycling through medications, tolerating side effects, and managing the emotional toll of repeated disappointment.
The reasons depression resists conventional treatment are varied and still being studied. For some patients, the serotonin-focused mechanism of most antidepressants simply doesn’t address their brain’s particular neurochemical imbalance. Others may have underlying inflammation, hormonal factors, or structural brain changes that blunt the effectiveness of traditional approaches. To better understand the full spectrum of conditions involved, it helps to explore what mood disorders are and how they differ from one another. What’s clear is that TRD isn’t a reflection of personal failure or insufficient effort—it’s a neurobiological reality that requires a different treatment strategy.
Here in Orange County, where the pressure to maintain high performance in careers, relationships, and daily life is relentless, treatment-resistant depression carries an additional burden: the expectation that you should be able to simply try harder, think more positively, or push through. Understanding that TRD has roots in brain chemistry, not willpower, is the first step toward finding relief.
How Traditional Antidepressants Work—and Where They Fall Short
Most conventional antidepressants—SSRIs like sertraline and fluoxetine, SNRIs like venlafaxine and duloxetine—work by modulating serotonin and norepinephrine levels in the brain. These neurotransmitters play important roles in mood regulation, and for many people, increasing their availability provides meaningful relief. The challenge is that this approach targets only one part of a complex neurochemical landscape, which is why patients dealing with a range of mood disorders often find that conventional medications leave significant symptoms unaddressed.
The serotonin hypothesis of depression, while useful, has increasingly been recognized as incomplete. A landmark 2022 umbrella review published in Molecular Psychiatry examined decades of research and concluded that the evidence does not consistently support the idea that depression is caused primarily by low serotonin levels. This doesn’t mean SSRIs don’t work—they do for many people—but it helps explain why they don’t work for everyone, and why a fundamentally different mechanism of action may be needed for those with TRD.
Beyond efficacy concerns, the timeline of traditional antidepressants presents its own challenge. Most require four to six weeks before patients notice meaningful improvement, and finding the right medication and dosage often involves multiple trials spanning months. For someone in the depths of severe depression, that waiting period can feel unbearable.
Ketamine’s Different Mechanism: The Glutamate Pathway
This is where ketamine therapy enters the picture, and why it represents a genuine paradigm shift rather than simply another medication to try. Unlike serotonin-based antidepressants, ketamine primarily acts on the brain’s glutamate system—specifically by blocking NMDA receptors. Glutamate is the most abundant excitatory neurotransmitter in the brain, and its role in depression has become one of the most exciting areas of psychiatric research over the past two decades.
When ketamine blocks NMDA receptors, it triggers a cascade of downstream effects that are fundamentally different from what happens with traditional antidepressants. The most significant of these is a rapid increase in brain-derived neurotrophic factor, or BDNF, sometimes called the brain’s “fertilizer.” BDNF promotes the growth of new synaptic connections between neurons—a process called synaptogenesis—and strengthens existing ones. Research published in Science (2010) by Ronald Duman and colleagues at Yale demonstrated that a single dose of ketamine could rapidly increase synaptic connections in the prefrontal cortex of animal models, reversing the damage caused by chronic stress.
What this means in practical terms is that ketamine doesn’t just adjust the levels of chemicals floating between neurons. It helps rebuild the neural infrastructure itself. Depression, particularly chronic and treatment-resistant depression, is associated with actual physical changes in the brain: reduced synaptic density, decreased connectivity between regions involved in mood regulation, and shrinkage in areas like the hippocampus and prefrontal cortex. Ketamine’s ability to promote neuroplasticity directly addresses these structural deficits.
The Speed Factor: Relief in Hours, Not Weeks
Perhaps the most remarkable aspect of ketamine therapy for TRD is its speed of action. A pivotal 2006 study published in the Archives of General Psychiatry by Carlos Zarate and colleagues at the National Institute of Mental Health found that a single intravenous dose of ketamine produced rapid antidepressant effects within hours in patients with treatment-resistant depression, with the majority of participants experiencing significant improvement within 24 hours.
This rapid onset isn’t just clinically impressive—it’s life-changing for patients who have spent months or years waiting for medications to take effect. The psychological impact of feeling genuine relief within hours after years of numbness cannot be overstated. Many patients describe it as remembering what it feels like to be themselves.
Michael, a 52-year-old architect from Laguna Beach, had tried seven different antidepressants over twelve years. “After my first ketamine infusion, I drove home and noticed the sunset. That sounds small, but I hadn’t actually noticed beauty in anything for years. My wife said I looked like a different person that evening. For the first time, I believed something could actually help me.”
What the Research Shows
The evidence base for ketamine’s effectiveness in TRD has grown substantially. A 2019 meta-analysis published in the Journal of Clinical Psychiatry analyzed multiple randomized controlled trials and found that intravenous ketamine produced response rates significantly higher than placebo in patients with treatment-resistant depression, with effects observed as early as 24 hours post-infusion. A comprehensive review in the American Journal of Psychiatry (2018) confirmed these findings and noted that repeated infusions could extend the duration of antidepressant effects.
It’s important to note that while ketamine’s effects are rapid, they are also time-limited following a single infusion—typically lasting one to two weeks. This is why treatment protocols at clinics like OC Ketamine Therapy involve a series of infusions, usually six sessions over two to three weeks, followed by maintenance treatments as needed. Research suggests that this approach provides the most sustained benefit, allowing the neuroplastic changes to consolidate.
The Treatment Experience at OC Ketamine Therapy
Understanding the science is important, but knowing what to expect practically matters just as much. At OC Ketamine Therapy in Newport Beach, each patient begins with a comprehensive evaluation with Dr. Seif to determine whether ketamine therapy is appropriate and to develop a personalized treatment plan. This consultation process is essential—ketamine isn’t right for everyone, and a thorough assessment ensures both safety and the best chance of a positive outcome.
During an infusion, patients relax in a comfortable, spa-like setting while the medication is administered intravenously over approximately 40 to 60 minutes. Vital signs are monitored throughout. For a full picture of what the process looks like from start to finish, our post on inside a ketamine infusion walks through each stage in detail. Most patients experience a mild dissociative state—a dreamlike quality that many describe as feeling both deeply relaxed and mentally expansive. The clinical team remains present to ensure comfort and safety at every stage.
What sets practices like OC Ketamine Therapy apart is the emphasis on integration: helping patients translate the neuroplastic window that ketamine opens into lasting behavioral and emotional change. This might include elements of ketamine-assisted psychotherapy, like guided meditation, journaling, mindfulness practices, breathwork, or coordination with a patient’s existing therapist to maximize the benefits of each session.
Is Ketamine Therapy Right for Your Depression?
Ketamine therapy is most commonly recommended for patients who have not responded adequately to at least two conventional antidepressants. It’s also considered for patients experiencing active suicidal ideation, given its rapid onset of action. However, it’s not appropriate for everyone—patients with certain medical conditions, a history of psychosis, or active substance use disorders may not be candidates. If you have questions or concerns about whether this treatment fits your situation, reviewing our resource on debunking common misconceptions about ketamine can help set realistic expectations.
The decision to explore ketamine therapy is deeply personal and should be made in consultation with a qualified provider. If you’ve been carrying the weight of treatment-resistant depression and wondering whether anything different exists, the answer is yes. The neuroscience has caught up with the clinical reality, and for many patients, ketamine represents the breakthrough they’ve been searching for.
Taking the Next Step
If traditional treatments haven’t provided the relief you deserve, know that treatment-resistant depression is not a dead end. Our team at OC Ketamine Therapy in Newport Beach, California, specializes in helping patients who have been told they’ve “tried everything.” Schedule a complementary discovery call to discuss whether ketamine therapy might be the next chapter in your healing journey.
References
Zarate, C. A., Singh, J. B., Carlson, P. J., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864. https://doi.org/10.1001/archpsyc.63.8.856
Li, N., Lee, B., Liu, R. J., et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959–964. https://doi.org/10.1126/science.1190287
Moncrieff, J., Cooper, R. E., Stockmann, T., et al. (2022). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry, 28, 3243–3256. https://doi.org/10.1038/s41380-022-01661-0
Caddy, C., Amit, B. H., McCloud, T. L., et al. (2015). Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews, (9). https://doi.org/10.1002/14651858.CD011612.pub2
Murrough, J. W., Iosifescu, D. V., Chang, L. C., et al. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392
About Dr. Dina Seif
Dina Seif, MD, believes that with the right mindset and support, every one of us has the potential to transform and heal our minds. She specializes in creating a personalized plan for each patient and is committed to providing a supportive healing environment for your journey.
Dr. Seif is a member of the American Society of Ketamine Physicians and was recognized as a Physician of Excellence by the Orange County Medical Association. Dr. Seif has 15+ years of experience with ketamine in the emergency setting and founded one of the first ketamine practices in Orange County in 2019. She has administered thousands of infusions and cared for hundreds of patients from around the world, bringing deep clinical experience to those struggling with severe depression and guiding them toward renewed hope and well-being.
Dr. Seif is board-certified in Emergency Medicine. She is a graduate of the University of California, Irvine, where she attended college, medical school, and business school.
After an internship in Internal Medicine at St. Vincent’s Medical Center in New York, she returned to California for Emergency Medicine residency at LAC+USC Medical Center where she also completed a fellowship in Emergency Ultrasound and was a Professor of Clinical Emergency Medicine at Keck School of Medicine of USC for 5 years.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. If you are experiencing a mental health crisis or having thoughts of self-harm, please call 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room immediately. The information provided here is not intended to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any new treatment or making changes to existing treatment plans. Individual results may vary, and what works for one person may not work for another.